KEY WORDS ACC Expert Consensus Decision Pathway, ARNI, heart failure, HFrEF, SGLT2 inhibitor Maddox et al. J Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Bene t Expert Witness Thomas M. Maddox (Chair) BJC HealthCare and Washington University School of Medicine Executive Director, Healthcare Innovation Lab; Professor of Medicine None None None None None None James L. Januzzi Jr. (Vice Chair) Harvard Medical School Hutter Family Professor of Medicine; Director, Dennis and Marilyn Barry Fellowship in Cardiology Research; Senior Cardiometabolic Faculty, Baim Institute for Clinical Research n Abbott n Roche Diagnostics* None None n Abbott* n Amgen (DSMB)* n Boehringer Ingel- heim (DSMB)* n Janssen Pharmaceu- ticals (DSMB)* n Novartis* None None Larry A. Allen University of Colorado School of Medicine Associate Professor of Medicine n Abbott n Amgen n Boston Scienti c n Novartis None None None n Janssen None Khadijah Breathett University of Arizona College of Medicine Assistant Professor of Medicine, Division of Cardiology, Advanced Heart Failure and Transplant None None None None None None Javed Butler University of Mississippi Medical Center Patrick H. Lehan Professor; Chairman, Department of Medicine n Abbott n AstraZeneca n Boehringer Ingelheim* n Eli Lilly* n Janssen* n Medtronic n Novartis* n Relypsa* n Roche Diagnostics n Janssen* n Novartis* None n Amgen (DSMB) n Bristol-Myers Squibb (DSMB) None None Leslie L. Davis University of North Carolina at Chapel Hill Associate Professor of Nursing None None None None n AANP None Gregg C. Fonarow David Geffen School of Medicine, UCLA Division of Cardiology Professor of Medicine n Abbott* n Amgen n AstraZeneca n CHF Solutions Lifesciences* n Janssen n Medtronic n Novartis* None None None n Boston Scienti c None Continued on the next page APPENDIX 1. 